REDUCE-IT Will Test Risks Of Weakening Protection Of FDA-Labeled Claims
Executive Summary
Amarin spent five years and lots of money to show Vascepa reduced the risk of cardiovascular events. REDUCE-IT trial results will test what Amarin will get for conducting the trial and whether the company’s off-label argument could work against them.
You may also be interested in...
Vascepa Advisory Committee Is Latest Outpost In Product's Remarkable Regulatory Journey
The last time representatives from Amarin and US FDA formally met in public, it was in court.
Consumer-Focused Off-Label Promotion Seems Possible After Amarin Settlement
Legal agreement with FDA allowing communication about off-label Vascepa use is not limited by audience, speaker or setting, attorneys say.
US Medicare Plans 'Can' Cover Wegovy, CMS Says, But Will They?
Medicare is making clear that Part D ‘can’ cover GLP-1 inhibitors that are approved for cardiovascular indications – but in language that seems to leave plans considerable discretion for now. The formulary review process for 2025 may be a more important milestone for changes.